Last reviewed 2026-04-20 · How we verify

PF-06821497 Treatment A (pf-06821497-treatment-a)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Headache
• Vessel puncture site bruise
• Nail avulsion
• Neck pain
• Disturbance in attention
• Eyelid pain
• abdominal discomfort
• Abdominal pain
• Constipation
• Nausea
• Vessel puncture site pain
• Fall

Key clinical trials

• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (PHASE1)
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (PHASE3)
• A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (PHASE1)
• A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults (PHASE1)
• A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PF-06821497 Treatment A CI brief — competitive landscape report
• PF-06821497 Treatment A updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI